Sunday, March 3, 2024

Yorkshire medtech firm raises £2.5m

A Yorkshire medtech company which has developed a device that could improve the success of knee replacement surgery has raised £2.5m in a Series A funding round.

Eventum Orthopaedics has secured funding from NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund, Mercia’s EIS funds and private investors, some of whom are orthopaedic surgeons.

Eventum’s Quadsense device measures the forces of a patient’s quadriceps muscles across the range of leg motions before and during surgery, enabling surgeons to position the kneecap in such a way that the patient retains the same muscle balance and regains normal knee function.

The Ilkley-based company was founded in 2020 by John Naybour and Paul Atherton, who between them have almost 50 years’ experience in developing and marketing orthopaedic devices. They designed Quadsense with input from leading surgeons worldwide. The company raised an initial £1.4m from NPIF – Mercia Equity Finance and private investors in 2021 to help it develop the product and gain regulatory approval.

It has now achieved UK CA approval and the ISO13485 standard for medical devices, and has been used in 20 operations in New Zealand in conjunction with robotic surgery. The latest funding will enable the company to begin production, expand its sales and technical team and apply for FDA approval in the US. Eventum currently employs a team of five but plans to expand that to 12 in the year ahead.

Globally, around 2 million patients a year have knee replacements, with the figure expected to rise to 3.5m by 2030. However as many as one in five suffer ongoing pain or are dissatisfied with the outcome of their surgery. Eventum believes the key to improving success rates is the position of the kneecap, which plays a crucial role in the knee’s function.

John Naybour, Eventum’s CEO, said: “The Eventum team have done a massive amount of work in a short space of time in developing Quadsense and getting it approved for clinical use. We are now excited to start scaling up the team to commercialise the product, as well as bringing further innovations to the orthopaedics market.”

Connie Smith of Mercia added: “Whilst total knee implants have a great track record in terms of survival rates, up to 20% of recipients are still dissatisfied with their outcome. Eventum is pioneering a new approach using sensor technology and machine learning to provide accurate measurements and remove the guesswork associated with current procedures. John and his team have made great progress with the initial funding and this latest round will enable them to roll out the product to the global marketplace.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemichaving a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.








Latest news

Related news